Pidotimod in pediatrics: new evidence and future perspectives
Keywords:
Pidotimod, add-on strategy , allergy, asthma, respiratory infectionsAbstract
Pidotimod is a synthetic dipeptide that exerts immunomodulatory activity, modifying innate and adaptive immunity. Pidotimod firstly acts on Toll-like receptors, then on antigen-presenting cells and other immunocompetent cells. Pidotimod also affects immunoglobulin production and their switching. Evidence shows that pidotimod effectively and safely prevents respiratory infections, mainly in children with recurrent and frequent infectious episodes. In addition, pidotimod may be helpful as an add-on strategy in managing children with infections. Finally, there is evidence that pidotimod, thanks to its immunomodulatory activity and preventing respiratory infections (the main trigger for asthma exacerbation), may be beneficial in managing subjects with asthma and allergic diseases. The present review presents and discusses the most recent studies conducted in children with asthma, allergic rhinitis, recurrent respiratory infections and acute infections. Lastly, pidotimod is safe and well-tolerated in children.
References
Centers for Disease Control and Prevention. Information on diseases & conditions for parents with children (ages 4-11) [Internet]. [Accessed 2023 25 Oct]. Available from: https://www.cdc.gov/parents/children/diseases_conditions.html
Ministry of Health Singapore. Childhood illnesses: 10 most common conditions in children [Internet]. [Accessed 2023 25 Oct]. Available from: https://www.healthhub.sg/a-z/diseases-and-conditions/640/top-10-common-childhood-conditions-ehb
Tosca MA, Schiavetti I, Duse M, Marseglia GL, Ciprandi G, Asthma Committee of the SIAIP. A survey on the management of children with asthma in primary care setting in Italy. Pediatr Allergy Immunol Pulmonol. 2021 Jun;34(2):39-42.
Bousquet J, Melen E, Haahtela T, Koppelman GH, Togias A, Valenta R, et al. Rhinitis associated with asthma is distinct from rhinitis alone: the ARIA-MeDALL hypothesis. Allergy. 2023 May;78(5):1169-203.
Wu S, Wang Z, Zhu Y, Zhu X, Guo L, Fu Y, et al. MiR-223-3p regulates the eosinophil degranulation and enhances the inflammation in allergic rhinitis by targeting FBXW7. Int Immunopharmacol. 2023 May;118:110007.
Ciprandi G, Tosca MA, Fasce L. Allergic children have more numerous and severe respiratory infections than non-allergic children. Pediatr Allergy Immunol. 2006 Aug;17(5):389-91.
Varricchio A, La Mantia I, Brunese FP, Ciprandi G. Inflammation, infection, and allergy of upper airways: new insights from national and real-world studies. Ital J Pediatr. 2020 Feb 10;46(1):18.
Passalacqua G, Ciprandi G, Pasquali M, Guerra L, Canonica GW. An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol. 2004 Jun;4(3):177-83.
Rahimi RA, Sokol CL. Functional recognition theory and type 2 immunity: insights and uncertainties. Immunohorizons. 2022 Aug 4;6(8):569-80.
Cicchella A, Stefanelli C, Massaro M. Upper respiratory tract infections in sport and the immune system response. A review. Biology (Basel). 2021 Apr 23;10(5):362.
Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021 Jul 5;218(7):e20201544.
Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: an overview. Ann Allergy Asthma Immunol. 2021 Dec;127(6):617-26.
Pawelec G. Age and immunity: What is "immunosenescence"? Exp Gerontol. 2018 May;105:4-9.
Ciprandi G, Tosca MA. Nutraceuticals and non-pharmacological remedies for managing patients with allergic rhinitis. Minerva Pediatr (Torino). 2022 Oct 25.
Ciprandi G, Tosca MA. Non-pharmacological remedies for the common cold. Minerva Pediatr (Torino). 2023 Feb;75(1):75-86.
Ciprandi G, Aragona SE. Non-pharmacological remedies for upper respiratory diseases in the pandemic COVID-19 era. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):41-9.
Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional herbal medicine candidates as complementary treatments for COVID-19: A review of their mechanisms, pros and cons. Evid Based Complement Alternat Med. 2020;2020:2560645.
Esposito S, Jones MH, Feleszko W, Martell JAO, Falup-Pecurariu O, Geppe N, et al. Prevention of new respiratory episodes in children with recurrent respiratory infections: an expert consensus statement. Microorganisms. 2020 Nov 17;8(11):1810.
Feleszko W, Rossi GA, Krenke R, Canonica GW, Van Gerven L, Kalyuzhin O. Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases. Expert Rev Respir Med. 2020 Jun;14(6):603-19.
Ferrario BE, Garuti S, Braido F, Canonica GW. Pidotimod: the state of art. Clin Mol Allergy. 2015;13(1):8.
Manikam L, Reed K, Venekamp RP, Hayward A, Littlejohns P, Schilder A, et al. Limited evidence on the management of respiratory tract infections in Down's syndrome: a systematic review. Pediatr Infect Dis J. 2016 Oct;35(10):1075-9.
Manti S, Parisi GF, Papale M, Leonardi S. Pidotimod in allergic diseases. Minerva Pediatr. 2020 Oct;72(5):358-63.
Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, et al. Immunostimulants in respiratory diseases: focus on pidotimod. Multidiscip Respir Med. 2019;14:31.
Zhang W, Huang J, Liu H, Wen X, Zheng Q, Li L. Whether immunostimulants are effective in susceptible children suffering from recurrent respiratory tract infections: a modeling analysis based on literature aggregate data. J Clin Pharmacol. 2022 Feb;62(2):245-53.
Zhao N, Liu C, Zhu C, Dong X, Liu X. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-18.
Mahashur A, Thomas PK, Mehta P, Nivangune K, Muchhala S, Jain R. Pidotimod: In-depth review of current evidence. Lung India. 2019 Sep-Oct;36(5):422-33.
Maillard F. Pidotimod. A new biological response modifier. Introduction. Arzneimittelforschung. 1994 Dec;44(12A):1399-401.
Borghi MO, Minonzio F, Fain C, Carbonelli V, Barcellini W, Del Papa N, et al. Effect of pidotimod on the function of the human immune system: in vitro and ex vivo study [in Italian]. Drugs Exp Clin Res. 1993;19 Suppl:37-43.
Licari A, Manti S, Castagnoli R, Marseglia A, Foiadelli T, Brambilla I, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
Dal Bo L, Broccali GP, Silingardi S, Coppi G. A new HPLC method for pidotimod plasma levels determination. Boll Chim Farm. 1993 Apr;132(4):126-8.
D'Angelo L, De Ponti F, Crema F, Caravaggi M, Crema A. Effect of food on the bioavailability of pidotimod in healthy volunteers. Arzneimittelforschung. 1994 Dec;44(12A):1473-5.
Manzardo S, Falcone A, Pinzetta A, Ieva G, Coppi G. General pharmacology of pidotimod and testing for drug interactions. Arzneimittelforschung. 1994 Dec;44(12A):1441-7.
Auteri A, Pasqui AL, Bruni F, Saletti M, Di Renzo M, Bova G. Effect of pidotimod, a new immunostimulating agent, on some aspects of immune response. In vitro study. Pharmacol Res. 1992 Sep;26 Suppl 2:196-7.
Zuccotti GV, Mameli C. Pidotimod: the past and the present. Ital J Pediatr. 2013 Dec 6;39:75.
Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185.
Deglurkar R, Mathew JL, Singh M. Efficacy and safety of pidotimod in persistent asthma: A randomized triple-blinded placebo-controlled trial. Indian Pediatr. 2022 Mar 15;59(3):201-5.
Brindisi G, Zicari AM, Schiavi L, Gori A, Conte MP, Marazzato M, et al. Efficacy of pidotimod use in treating allergic rhinitis in a pediatric population. Ital J Pediatr. 2020 Jul 7;46(1):93.
Zhai F, Liu X. The effect of pidotimod in the prevention and treatment of pediatric bronchial asthma. Chin J Biochem Pharm 2011;32(2):151-5.
Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Int Arch Allergy Immunol. 2004 May;134(1):34-40.
de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol. 2007 Nov;18 Suppl 18:13-8.
Chiappini E, Santamaria F, Marseglia GL, Marchisio P, Galli L, Cutrera R, et al. Prevention of recurrent respiratory infections: inter-society consensus. Ital J Pediatr. 2021 Oct 25;47(1):211.
Bozzetto S, Pirillo P, Carraro S, Berardi M, Cesca L, Stocchero M, et al. Metabolomic profile of children with recurrent respiratory infections. Pharmacol Res. 2017 Jan;115:162-7.
Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008 Oct 23;455(7216):1054-6.
Li X, Li Q, Wang X, Lu M, Shen J, Meng Q. Pidotimod in the treatment of pediatric recurrent respiratory tract infection. Pak J Med Sci. 2019 Jul-Aug;35(4):981-6.
Santamaria F, Montella S, Stocchero M, Pirillo P, Bozzetto S, Giordano G, et al. Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2019 Oct;58:101818.
Valentini D, Di Camillo C, Mirante N, Marcellini V, Carsetti R, Villani A. Effects of pidotimod on recurrent respiratory infections in children with Down syndrome: a retrospective Italian study. Ital J Pediatr. 2020 Mar 13;46(1):31.
McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. J Pediatr. 2011 Feb;158(2):319-25.
Xu B, Li X, Hu S, Bao Y, Chen F, Chen Z, et al. Safety and efficacy of Yupingfeng granules in children with recurrent respiratory tract infection: A randomized clinical trial. Pediatr Investig. 2022 Jun;6(2):75-84.
Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019 Feb;67:35-45.
Buendía JA, Guerrero Patiño D, Lindarte EF. Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022 Jun 23;22(1):244.
Shi H, Lan L, Lv X, Sun L. Effect of pidotimod combined with azithromycin on children with mycoplasma pneumonia and the expression levels of IL-10 and G-CSF in serum. Exp Ther Med. 2019 Sep;18(3):1800-6.
Sylvester JE, Buchanan BK, Silva TW. Infectious mononucleosis: rapid evidence review. Am Fam Physician. 2023 Jan;107(1):71-8.
Lyu HT, Shen TT, Zheng JS, Xu HQ. Clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis [in Chinese]. Zhongguo Dang Dai Er Ke Za Zhi. 2018 Jul;20(7):563-6.
La Mantia I, Varricchio A, Andaloro C, Ciprandi C. Pidotimod in children with infectious mononucleosis: a preliminary randomized controlled study. J Biol Regul Homeost Agents. 2020 Jul-Aug;34(4):1597-9.
Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987 Jan;110(1):43-6.
Vanoni F, Theodoropoulou K, Hofer M. PFAPA syndrome: a review on treatment and outcome. Pediatr Rheumatol Online J. 2016 Jun 27;14(1):38.
Manti S, Filosco F, Parisi GF, Finocchiaro GG, Papale M, Giugno A, et al. Proposal for a new therapeutic high dosage of pidotimod in children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: a randomized controlled study. Ital J Pediatr. 2020 Jul 25;46(1):106.
Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983 Jul;148(1):131-7.
Ucciferri C, Vecchiet J, Auricchio A, Falasca K. Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by pidotimod supplementation. Mediterr J Hematol Infect Dis. 2022;14(1):e2022023.
Chatterjee AN, Al Basir F. A model for SARS-CoV-2 infection with treatment. Comput Math Methods Med. 2020;2020:1352982.
Larenas-Linnemann D, Rodríguez-Pérez N, Arias-Cruz A, Blandón-Vijil MV, Del Río-Navarro BE, Estrada-Cardona A, et al. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions. World Allergy Organ J. 2020 Nov;13(11):100476.
Mahashur A, Vora A, Waghray P, Jafrey SZ, Karadkhele A, Muchhala S, et al. Expert opinion on usage of pidotimod in adult patients with chronic obstructive pulmonary disease: an Indian perspective. J Assoc Physicians India. 2021 Sep;69(9):11-2.
Santus P, Radovanovic D, Garziano M, Pini S, Croce G, Fuccia G, et al. Anti-inflammatory effects of immunostimulation in patients with COVID-19 pneumonia. J Clin Med. 2021 Dec 9;10(24):5765.
Ucciferri C, Barone M, Vecchiet J, Falasca K. Pidotimod in paucisymptomatic SARS-CoV2 infected patients. Mediterr J Hematol Infect Dis. 2020;12(1):e2020048.
Ucciferri C, Di Gasbarro A, Borrelli P, Di Nicola M, Vecchiet J, Falasca K. New therapeutic options in mild moderate COVID-19 outpatients. Microorganisms. 2022 Oct 27;10(11):2131.
Ucciferri C, Moffa L, Moffa S, Vecchiet J, Falasca K. Are monoclonal antibodies effective in patients with severe obesity in SARS-CoV-2 infected? Immun Inflamm Dis. 2023 Feb;11(2):e771.
Published
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
